BMS-Pfizer Alliance partners with Mark Cuban Cost Plus Drugs to expand eliquis access
Share
In a significant move for pharmaceutical transparency, the Bristol Myers Squibb-Pfizer Alliance announced that Eliquis® (apixaban), one of the world’s most widely prescribed blood thinners, will soon be available through Mark Cuban’s direct-to-consumer pharmacy.